TheraP Study: Lu-PSMA vs. cabazitaxel #ASCO20 #ANZUP
Channel: ProsTIC TV
Date: 2020-08-22

A randomised phase II trial of 177Lu-PSMA-617 (Lu-PSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results

Presented by Professor Michael Hofman on behalf of co-authors:
Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony Joshua, Jeffrey Goh, David Pattison, Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn Francis, Craig Gedye, Natalie Rutherford, Alison Zhang, Margaret McJannett, Martin Stockler, John Violet, Scott Williams, Andrew Martin, Ian Davis

TheraP is a partnership between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) in collaboration with the NHMRC CTC and the Australasian Radiopharmaceutical Trials Network (ARTnet) with support from the Australian Nuclear Science and Technology Organisation (ANSTO) and Endocyte Inc., a Novartis company.

Clinicaltrials.gov NCT03392428